Low-Dose Decitabine Plus Venetoclax As Frontline Treatment of Acute Myeloid Leukemia

Hypomethylating agents (HMAs) (5-azacytidine or decitabine) in combination with venetoclax is standard of care in the management of elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Nevertheless, treatment toxicity, in particular bone marrow suppression remains a challenging treatment-related aspect in the care of these patients. Lower than standard dose of decitabine (low-dose decitabine) exerts its effect via induction of cellular differentiation by epigenetic regulation, thus avoiding generalized cytotoxic effects.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mareike Peters, Ciprian Jitaru, Anamaria Bancos, Adrian Bogdan Tigu, Diana Cenariu, Cristina Selicean, Vlad Moisoiu, Petra Rotariu, Maria Santa, Sabina Iluta, Rares Drula, David Kegyes, Mihnea Zdrenghea, Ciprian Tomuleasa, Gabriel Ghiaur Tags: 139 Source Type: research